Cuprina Holdings Completes IVF Media Production Facility
Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR), a pioneering biomedical and biotechnology company, has achieved a significant milestone with the completion of its in-vitro fertilization (IVF) media production facility in Singapore. This accomplishment, announced on May 5, 2025, marks an important step in the Company’s mission to innovate solutions for chronic wounds, infertility, and the health and beauty markets.
ISO Certification and Dealer License
On April 6, 2025, Cuprina secured ISO 13485 certification, confirming that the facility's quality management system aligns with international standards for medical device manufacturing. This esteemed certification was granted by the United Kingdom Accreditation Service (UKAS). Furthermore, the Company obtained a dealer license from the Singapore Health Sciences Authority (HSA), permitting it to engage in essential activities such as manufacturing, importing, and wholesaling medical devices.
Partnership with Ferti-Craft
The facility was constructed through a strategic agreement with Ferti-Craft Pte Ltd., a Singaporean medtech firm known for its focus on advanced reproductive technologies. Cuprina and Ferti-Craft will collaborate closely to prepare and submit regulatory dossiers necessary for HSA approval to market 14 distinct IVF media product SKUs. This collaboration aims to utilize Ferti-Craft’s expertise in human-assisted reproductive technology to ensure that the products meet market needs effectively.
Goals for 2026
Cuprina’s objective is to achieve approval for commercial sale of these IVF products by the fourth quarter of 2026. With Ferti-Craft at the helm for documentation and logistics concerning raw materials, the facility is set to adhere to stringent production requirements and timelines. Initial market entry is planned within Singapore, followed by potential expansion into other ASEAN markets, the Middle East, and globally.
Innovation in Reproductive Technology
David Quek, Cuprina’s CEO, expressed enthusiasm about this collaboration, highlighting the significance of establishing such facilities in Singapore. The IVF media production facility represents a first for local operations in the country, with Cuprina’s background in setting up ISO 13485-compliant facilities giving them a distinct advantage.
Co-founder of Ferti-Craft, Jai Thampi, reinforced the value of partnering with Cuprina, noting their proven capabilities to meet international manufacturing standards, crucial for the development of effective IVF media.
Market Insights
The assisted reproductive technology (ART) landscape is expanding rapidly. Recent studies indicated that the total ART market was valued at $34.7 billion and is projected to reach $62.8 billion by 2032, growing at a rate of 6.9%. This surge can be attributed to the increased awareness regarding infertility solutions and novel ART approaches.
About Cuprina Holdings
Cuprina Holdings (Cayman) Limited is deeply committed to advancing biomedical technology for chronic wound management and reproductive health products. With a focus on innovative solutions derived from natural sources, the Company maintains high standards to ensure safety and efficacy in products for health and beauty. For further inquiries about Cuprina's offerings, please contact their investor relations team.
Frequently Asked Questions
What is Cuprina Holdings known for?
Cuprina Holdings focuses on developing innovative biomedical products for chronic wound management and infertility treatments.
Where is the new IVF media production facility located?
The facility is located in Singapore and is the first of its kind established by a local company.
What certifications has the facility received?
The facility has attained ISO 13485 certification and a dealer license from the Singapore Health Sciences Authority.
What partnerships support Cuprina's new facility?
Cuprina has partnered with Ferti-Craft, a medtech company, to leverage expertise in the production of IVF media products.
What is the expected market for the produced IVF media?
Initially, sales are planned for Singapore, with potential expansions into ASEAN countries and globally.
